AQR Capital Management
CASC

AQR Capital Management’s Cascadian Therapeutics, Inc. CASC Stock Holding History

AQR Capital Management’s Portfolio CASC Stock Details CASC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-20,203
Closed -$154K – 2315
2016
Q1 		$154K Buy
20,203
+7,434
+58% +$57.2K ﹤0.01% 2143
2015
Q4 		$170K Buy
12,769
+6,578
+106% +$113K ﹤0.01% 2177
2015
Q3 		$102K Buy
+6,191
New +$127K ﹤0.01% 2127
2014
Q4 		– Sell
-3,833
Closed -$44K – 2702
2014
Q3 		$44K Sell
3,833
-1,034
-21% -$15.8K ﹤0.01% 2486
2014
Q2 		$95K Buy
+4,867
New +$85.9K ﹤0.01% 2465

Other funds holding CASC

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
EAM
EverPoint Asset Management Stamford, Connecticut $5.38B AUM 21.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

AQR Capital Management's CASC Position: Q2 2016 in Review

AQR Capital Management sold out of Cascadian Therapeutics, Inc. (CASC) in Q2 2016, closing a stake of 20,203 shares — an estimated $154K sold.

AQR Capital Management first reported a position in CASC in Q2 2014 and held it in 5 quarters. The position peaked at $170K in Q4 2015. 75 funds tracked by Wall St. Rank hold CASC as of Q2 2016.

  • AQR Capital Management reported no remaining Cascadian Therapeutics, Inc. position as of Q2 2016 after selling out during the quarter.
  • AQR Capital Management sold 20,203 Cascadian Therapeutics, Inc. shares in Q2 2016, an estimated $154K.
  • AQR Capital Management first reported a position in Cascadian Therapeutics, Inc. in Q2 2014 and held it in 5 quarters.
  • AQR Capital Management's Cascadian Therapeutics, Inc. position peaked at $170K in Q4 2015.
  • 75 funds tracked by Wall St. Rank held Cascadian Therapeutics, Inc. as of Q2 2016.

Based on AQR Capital Management's 13F filing for Q2 2016, filed 15 Aug 2016.